Harmony Biosciences
HRMY
219 hedge funds and large institutions have $1.51B invested in Harmony Biosciences in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 75 increasing their positions, 74 reducing their positions, and 21 closing their positions.
67% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 21
5% more funds holding
Funds holding: 208 → 219 (+11)
2.03% more ownership
Funds ownership: 86.29% → 88.33% (+2%)
1% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 74
8% less capital invested
Capital invested by funds: $1.64B → $1.51B (-$131M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
47% less call options, than puts
Call options by funds: $1.47M | Put options by funds: $2.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cutter Capital Management
New York
|
+$8.89M |
| 2 |
Goldman Sachs
New York
|
+$7.35M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$7.31M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$7.16M |
| 5 |
Renaissance Technologies
New York
|
+$6.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$6.39M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.99M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$4.45M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$4.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.27M |
HRMY Hedge Fund Activity: Q2 2024 in Review
219 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2024, worth a combined $1.51B — down 8% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new HRMY positions and 21 closed out — a net gain of 14 holders — while 75 added to existing stakes and 74 trimmed.
The largest buyer was Cutter Capital Management, opening a new position worth an estimated $8.89M. The largest seller was Aberdeen Group, cutting an estimated $6.39M.
- 219 institutional investors held Harmony Biosciences (HRMY) as of Q2 2024, up from 208 in Q1 2024.
- Funds reported $1.51B of Harmony Biosciences stock for Q2 2024, down 8% quarter-over-quarter.
- 35 funds opened new Harmony Biosciences positions in Q2 2024 and 21 closed out, a net change of +14 holders.
- The largest Harmony Biosciences buyer in Q2 2024 was Cutter Capital Management, an estimated $8.89M added.
- The largest Harmony Biosciences seller in Q2 2024 was Aberdeen Group, an estimated $6.39M sold.
Based on aggregated 13F filings for Q2 2024.